Literature DB >> 21712425

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Amit K Mitra1, Kristine R Crews, Stanley Pounds, Xueyuan Cao, Tanya Feldberg, Yogita Ghodke, Varsha Gandhi, William Plunkett, M Eileen Dolan, Christine Hartford, Susana Raimondi, Dario Campana, James Downing, Jeffrey E Rubnitz, Raul C Ribeiro, Jatinder K Lamba.   

Abstract

Cytosolic 5'-nucleotidase II (NT5C2) is involved in the development of 1-β-d-arabinofuranosylcytosine (ara-C) resistance and has been associated with clinical outcome in patients receiving ara-C-based chemotherapy. NT5C2 inactivates ara-C by dephosphorylating ara-C monophosphate to ara-C. In this study, we sequenced NT5C2 in genomic DNA samples from International HapMap project panels with European [Centre d'Etude du Polymorphisme Humain (CEU); n = 90] or African [Yoruba people in Ibadan, Nigeria (YRI); n = 90] ancestry. We identified 41 genetic variants [one insertion-deletion and 40 single nucleotide polymorphisms (SNPs)], including three nonsynonymous SNPs (Y3A, K47R, and Q136R). Twenty-five SNPs were novel and 16 overlapped with the HapMap data. Subjects with African ancestry had NT5C2 mRNA expression levels that was significantly higher than those with European ancestry (p = 0.005). Furthermore, there was a correlation between NT5C2 mRNA expression and ara-C sensitivity in CEU but not in YRI cell lines. None of the nonsynonymous SNPs demonstrated any effect on NT5C2 activity. The genotypes of several SNPs were significantly associated with NT5C2 mRNA expression and/or ara-C sensitivity in CEU cell lines, but very few were significant in YRI cell lines. Of most interest, SNPs (linkage disequilibrium group CEU.12) in the 5'-untranslated region were associated with NT5C2 expression and ara-C sensitivity in HapMap cell lines and with NT5C2 mRNA expression and ara-C sensitivity in diagnostic leukemic blasts from pediatric patients with acute myeloid leukemia. Functional genomics analysis demonstrated that the promoter SNP rs11191612 was associated with altered luciferase activation in reporter assays and altered DNA-protein binding in gel shift assays. These results suggest that genetic variations in NT5C2 influence its expression and, potentially, cellular responses to nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21712425      PMCID: PMC3186292          DOI: 10.1124/jpet.111.182873

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

1.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.

Authors:  C Dumontet; K Fabianowska-Majewska; D Mantincic; E Callet Bauchu; I Tigaud; V Gandhi; M Lepoivre; G J Peters; M O Rolland; D Wyczechowska; X Fang; S Gazzo; D A Voorn; A Vanier-Viornery; J MacKey
Journal:  Br J Haematol       Date:  1999-07       Impact factor: 6.998

2.  Predicting deleterious amino acid substitutions.

Authors:  P C Ng; S Henikoff
Journal:  Genome Res       Date:  2001-05       Impact factor: 9.043

3.  A multiple testing procedure to associate gene expression levels with survival.

Authors:  Sin-Ho Jung; Kouros Owzar; Stephen L George
Journal:  Stat Med       Date:  2005-10-30       Impact factor: 2.373

Review 4.  What does over-expression of cN-II enzyme signify in haematological malignancies?

Authors:  Carlos M Galmarini
Journal:  Leuk Res       Date:  2007-04-16       Impact factor: 3.156

5.  The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.

Authors:  Carlos María Galmarini; Emeline Cros; Xavier Thomas; Lars Jordheim; Charles Dumontet
Journal:  Haematologica       Date:  2005-12       Impact factor: 9.941

6.  Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.

Authors:  Keijiro Suzuki; Takeshi Sugawara; Tatsuo Oyake; Toshiyuki Uchiyama; Yusei Aoki; Yasuhiko Tsukushi; Shima Onodera; Shigeki Ito; Kazunori Murai; Yoji Ishida
Journal:  Leuk Res       Date:  2007-03-12       Impact factor: 3.156

7.  Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides.

Authors:  A Amici; M Emanuelli; G Magni; N Raffaelli; S Ruggieri
Journal:  FEBS Lett       Date:  1997-12-15       Impact factor: 4.124

8.  Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Franklin O Smith; Soheil Meshinchi; Julie A Ross; John Perentesis; William G Woods; Beverly J Lange; Stella M Davies
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

9.  Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.

Authors:  M Schirmer; A P Stegmann; F Geisen; G Konwalinka
Journal:  Exp Hematol       Date:  1998-12       Impact factor: 3.084

10.  Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.

Authors:  A H Beesley; M-L Palmer; J Ford; R E Weller; A J Cummings; J R Freitas; M J Firth; K U Perera; N H de Klerk; U R Kees
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

View more
  27 in total

1.  RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Authors:  Xueyuan Cao; Amit K Mitra; Stanley Pounds; Kristine R Crews; Varsha Gandhi; William Plunkett; M Eileen Dolan; Christine Hartford; Susana Raimondi; Dario Campana; James Downing; Jeffrey E Rubnitz; Raul C Ribeiro; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs.

Authors:  Jason Saliba; Ryan Zabriskie; Rajarshi Ghosh; Bradford C Powell; Stephanie Hicks; Marek Kimmel; Qingchang Meng; Deborah I Ritter; David A Wheeler; Richard A Gibbs; Francis T F Tsai; Sharon E Plon
Journal:  Pharmacogenet Genomics       Date:  2016-06       Impact factor: 2.089

3.  Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.

Authors:  Uchenna O Njiaju; Eric R Gamazon; Lidija K Gorsic; Shannon M Delaney; Heather E Wheeler; Hae Kyung Im; M Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

4.  Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

Authors:  A K Mitra; U K Mukherjee; T Harding; J S Jang; H Stessman; Y Li; A Abyzov; J Jen; S Kumar; V Rajkumar; B Van Ness
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

Review 5.  Relating human genetic variation to variation in drug responses.

Authors:  Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Journal:  Trends Genet       Date:  2012-07-26       Impact factor: 11.639

6.  Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Authors:  Eric R Gamazon; Jatinder K Lamba; Stanley Pounds; Amy L Stark; Heather E Wheeler; Xueyuan Cao; Hae K Im; Amit K Mitra; Jeffrey E Rubnitz; Raul C Ribeiro; Susana Raimondi; Dario Campana; Kristine R Crews; Shan S Wong; Marleen Welsh; Imge Hulur; Lidija Gorsic; Christine M Hartford; Wei Zhang; Nancy J Cox; M Eileen Dolan
Journal:  Blood       Date:  2013-03-28       Impact factor: 22.113

7.  Genome-wide approaches in pharmacogenomics: heritability estimation and pharmacoethnicity as primary challenges.

Authors:  Eric R Gamazon; Minoli Perera
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

Review 8.  The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.

Authors:  Ashkan Emadi; Judith E Karp
Journal:  Pharmacogenomics       Date:  2012-08       Impact factor: 2.533

9.  PharmGKB summary: gemcitabine pathway.

Authors:  Maria L Alvarellos; Jatinder Lamba; Katrin Sangkuhl; Caroline F Thorn; Liewei Wang; Daniel J Klein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-11       Impact factor: 2.089

10.  Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.

Authors:  Abdelrahman H Elsayed; Xueyuan Cao; Kristine R Crews; Varsha Gandhi; William Plunkett; Jeffrey E Rubnitz; Raul C Ribeiro; Stanley B Pounds; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2018-08-08       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.